Overview A Study in Adults With Type 1 Diabetes Status: Completed Trial end date: 2013-04-01 Target enrollment: Participant gender: Summary The purpose of this study is to compare the effectiveness and safety of LY2963016 versus Lantus when taken once daily in combination with insulin lispro before meals three times a day. Phase: Phase 3 Details Lead Sponsor: Eli Lilly and CompanyCollaborator: Boehringer IngelheimTreatments: InsulinInsulin GlargineInsulin LisproInsulin, Globin Zinc